A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular CarcinomaLipika Goyal, Andrew X. Zhu, Hui Zheng et al.|Clinical Cancer Research|2018Cited by 82
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancerAram F. Hezel, Andrew X. Zhu, Marcus Smith Noel et al.|British Journal of Cancer|2014Cited by 58
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancerAndrew X. Zhu, Matthew H. Kulke, Jeffrey W. Clark et al.|Cancer Chemotherapy and Pharmacology|2006Cited by 32
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathyMaria Moscvin, Giada Bianchi, Eileen Regan et al.|Blood Cancer Journal|2023Cited by 20